Breaking News Instant updates and real-time market news.

KITE

Acquired by GILD 9/17

$51.69

-1.99 (-3.71%)

, BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

08:20
11/23/16
11/23
08:20
11/23/16
08:20

Kite Pharma, other CAR-T stocks fall after Juno puts trial on hold

Shares of Juno Therapeutics (JUNO) remain halted in pre-market trading after the company announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015, known as the "ROCKET" trial, after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover, Juno said. Other companies working on "CAR-T" therapies, a new class of oncology drugs that reengineer a patient's own cells to attack the disease, include Kite Pharma (KITE), which is down more than 6%, as well as ZIOPHARM Oncology(ZIOP) and bluebird bio (BLUE), which are each down nearly 6%. Juno shares are expected to resume trading at 8:30 am ET, according to Nasdaq.

KITE

Acquired by GILD 9/17

$51.69

-1.99 (-3.71%)

BLUE

bluebird bio

$60.95

-1.55 (-2.48%)

ZIOP

Ziopharm

$6.14

-0.27 (-4.21%)

JUNO

Juno Therapeutics

$29.88

-1.56 (-4.96%)

  • 29

    Nov

  • 29

    Nov

  • 03

    Dec

  • 03

    Dec

KITE Acquired by GILD 9/17
$51.69

-1.99 (-3.71%)

11/10/16
RBCM
11/10/16
NO CHANGE
RBCM
Kite Pharma weakness creates buying opportunity, says RBC Capital
After Kite's stock fell recently, RBC Capital analyst Michael Yee blames the pullback on macro worries about the biotech sector and a number of "short-term questions," about several issues, including upcoming ASH data, new durability data expected next quarter, and questions about the FDA's view of its drug. However, the analyst thinks that the company's comments indicate that its talks with the FDA are going well, and he says he remains upbeat on the company's pipeline. He expects "a lot" of concerns about the company to be mitigated in the next three to six m,months, as he thinks that it will report positive data in the near to medium term.The analyst keeps an $85 price target and an Outperform rating on the shares.
11/21/16
HCWC
11/21/16
INITIATION
Target $78
HCWC
Buy
Kite Pharma initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Kite Pharma with a Buy rating and $78 price target. While the competition for Chimeric Antigen Receptor T-cells is intense, Kite should have a big first-mover advantage with KTE-C19, Davis tells investors in a research note.
10/10/16
ADAM
10/10/16
NO CHANGE
Target $75
ADAM
Buy
Kite Pharma BLA filing still expected by year end, says Canaccord
Canaccord analyst John Newman noted Kite Pharma released 12 month update on Zuma-1 Phase 1, which showed durable efficacy and is encouraging despite coming from a small patient group. The analyst saw the release as a continuation of positive trends and expects a BLA filing by the end of 2016. Newman reiterated his Buy rating and $75 price target on Kite Pharma shares.
10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
BLUE bluebird bio
$60.95

-1.55 (-2.48%)

11/04/16
MAXM
11/04/16
NO CHANGE
Target $57
MAXM
Buy
bluebird bio price target lowered to $57 from $100 at Maxim
After bluebird released abstracts to be presented at the American Society of Hematology meeting in December, Maxim analyst Jason McCarthy said the "long-awaited" data for the next seven patients in the sickle cell study failed to impress, noting that the median vector copy number of corrected hemoglobin is low. Given expectations for longer timelines to get to Proof of Concept data in sickle cell, McCarthy has pushed back his expectations for a commercial launch in sickle cell to 2022 from 2020 and lowered his price target to $57 from $100, but given the potential in other program and the current valuation, he keeps a Buy rating on bluebird shares.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
BMO Capital initiated bluebird bio with a Market Perform rating and $61 price target.
11/10/16
BMOC
11/10/16
INITIATION
Target $61
BMOC
Market Perform
bluebird bio initiated with a Market Perform at BMO Capital
Analyst Matthew Luchini initiated bluebird with a Market Perform and a $61 price target.
11/11/16
11/11/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aegerion (AEGN) resumed with a Neutral at JPMorgan. 2. Lamb Weston (LW) initiated with a Buy at Stifel, initiated with an Overweight at Barclays, and an Equal Weight at Morgan Stanley. 3. bluebird bio (BLUE) initiated with a Market Perform at BMO Capital. 4. Alder Biopharmaceuticals (ALDR) initiated with an Outperform at BMO Capital. 5. ACADIA (ACAD) initiated with a Neutral at Goldman. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
ZIOP Ziopharm
$6.14

-0.27 (-4.21%)

12/04/15
12/04/15
INITIATION

On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Affimed Therapeutics (AFMD) initiated with an Outperform at Wells Fargo... American Farmland (AFCO) initiated with an Outperform at Raymond James... Amgen (AMGN) initiated with a Market Perform at Wells Fargo... Applied Genetic (AGTC) initiated with an Outperform at Wells Fargo... BCE (BCE) initiated with a Buy at Goldman... Capital Product (CPLP) initiated with a Buy at Janney Capital... Celestica (CLS) initiated with a Neutral at B. Riley... Colfax (CFX) initiated with a Perform at Oppenheimer... Dimension Therapeutics (DMTX) initiated with an Outperform at Wells Fargo... Dover (DOV) initiated with a Perform at Oppenheimer... Fate Therapeutics (FATE) initiated with an Outperform at Wells Fargo... FibroGen (FGEN) initiated with a Buy at Citi... Finish Line (FINL) initiated with a Hold at BB&T... Five Prime (FPRX) resumed with an Outperform at Wells Fargo... Foot Locker (FL) initiated with a Buy at BB&T... GWG Holdings (GWGH) initiated with a Buy at Roth Capital... General Growth (GGP) initiated with an Outperform at Boenning & Scattergood... GigOptix (GIG) initiated with a Buy at Sterne Agee CRT... Halozyme (HALO) initiated with an Outperform at Wells Fargo... Hasbro (HAS) initiated with a Hold at Jefferies... Infinera (INFN) initiated with an Outperform at Raymond James... Inphi (IPHI) initiated with a Buy at Sterne Agee CRT... Inter Parfums (IPAR) initiated with an Overweight at KeyBanc... Intercept (ICPT) initiated with a Market Perform at Wells Fargo... Isis Pharmaceuticals (ISIS) initiated with an Outperform at Wells Fargo... LinkedIn (LNKD) initiated with a Buy at Nomura... Macerich (MAC) initiated with an Outperform at Boenning & Scattergood... Markit (MRKT) initiated with a Hold at Cantor... Mattel (MAT) initiated with a Buy at Jefferies... Maximus (MMS) initiated with a Buy at Stifel... MyoKardia (MYOK) initiated with an Outperform at Wells Fargo... Nimble Storage (NMBL) initiated with an Overweight at JPMorgan... OncoMed (OMED) initiated with an Outperform at Wells Fargo... Patriot National (PN) initiated with a Buy at Compass Point... Pennsylvania REIT (PEI) initiated with a Neutral at Boenning & Scattergood... Pixelworks (PXLW) initiated with a Buy at Craig-Hallum... Qualcomm (QCOM) initiated with an Overweight at Pacific Crest... Regeneron (REGN) initiated with an Outperform at Wells Fargo... Regulus (RGLS) initiated with an Outperform at Wells Fargo... Rogers Communications (RCI) initiated with a Neutral at Goldman... Rouse Properties (RSE) initiated with a Neutral at Boenning & Scattergood... Sangamo (SGMO) initiated with an Outperform at Wells Fargo... Sanmina (SANM) initiated with a Buy at B. Riley... Simon Property (SPG) initiated with an Outperform at Boenning & Scattergood... TELUS (TU) initiated with a Neutral at Goldman... TESARO (TSRO) initiated with an Outperform at Wells Fargo... Tokai Pharmaceuticals (TKAI) initiated with an Outperform at Wells Fargo... Vitae Pharmaceuticals (VTAE) initiated with an Outperform at Wells Fargo... ZIOPHARM (ZIOP) initiated with an Underperform at Wells Fargo... bluebird bio (BLUE) initiated with an Outperform at Wells Fargo.
06/02/16
RAJA
06/02/16
INITIATION
RAJA
Market Perform
ZIOPHARM initiated with a Market Perform at Raymond James
07/15/16
JMPS
07/15/16
NO CHANGE
Target $42
JMPS
Outperform
JMP says ZIOPHARM trial death doesn't read through to other Intrexon programs
JMP Securities analyst Jason Butler said he views the patient death in ZIOPHARM's (ZIOP) Ad-RTS-IL-12 GBM trial as "possibly or even likely due to the study drug" and acknowledges the need for caution regarding the potential safety concerns of Ad-RTS-IL-12. However, while the trial death raises questions, Butler contends it has no read through to partner Intrexon's (XON) broader oncology programs. The analyst, who notes there are multiple other programs in or entering the clinic under the collaborations between ZIOPHARM and Intrexon, keeps an Outperform rating and $42 price target on Intrexon shares.
08/10/16
WELS
08/10/16
UPGRADE
WELS
Market Perform
ZIOPHARM upgraded to Market Perform from Underperform at Wells Fargo
Wells Fargo analyst Jim Birchenough upgraded ZIOPHARM Oncology to Market Perform citing valuation following the company's Q2 results. The analyst keeps a $5-$8 price target range for the shares.
JUNO Juno Therapeutics
$29.88

-1.56 (-4.96%)

11/03/16
BTIG
11/03/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
11/10/16
RHCO
11/10/16
NO CHANGE
RHCO
Juno Therapeutics drug could deliver best in class data, says SunTrust
SunTrust analyst Peter Lawson says that Juno's non-Hodgkin lymphoma,treatment, JCAR017, could deliver best in class data at ASH. The analyst reiterates a $48 price target and a Buy rating on the shares.
09/27/16
LEER
09/27/16
NO CHANGE
LEER
Outperform
Kite's ZUMA-1 interim data incrementally positive for Juno, says Leerink
Leerink analyst Michael Schmidt says Kite Pharma's (KITE) top-line interim results from its pivotal ZUMA-1 trial of anti-CD19 CAR-T product KTE-C19 in patients with chemorefractory diffuse large B-cell lymphoma, or DLBCL, are incrementally positive for Juno Therapeutics (JUNO). While Juno is roughly one year behind Kite in DLBCL, the analyst believes its JCAR017 holds the promise to have a compelling safety/efficacy profile in lymphoma and Acute Lymphoblastic Leukemia. He reiterates an Outperform rating on Juno's shares.
11/04/16
BTIG
11/04/16
UPGRADE
BTIG
Neutral
Juno Therapeutics upgraded to Neutral from Sell at BTIG
BTIG analyst Dane Leone upgraded Juno Therapeutics (JUNO) to Neutral from Sell citing valuation following the ASH abstract release showed similar response rates for JCAR017 versus Kite's (KITE) KTE-C19 in the treatment of patients with Diffuse Large B-Cell Lymphoma.

TODAY'S FREE FLY STORIES

FNSR

Finisar

$22.74

0.48 (2.16%)

08:41
01/16/18
01/16
08:41
01/16/18
08:41
Downgrade
Finisar rating change  »

Finisar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

, AVGO

Broadcom

$264.29

0.79 (0.30%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Earnings
Qualcomm 'firmly committed' to FY19 adjusted EPS target of $6.75-$7.50 »

As previously reported,…

QCOM

Qualcomm

$65.38

-0.05 (-0.08%)

AVGO

Broadcom

$264.29

0.79 (0.30%)

NXPI

NXP Semiconductors

$119.58

0.33 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

MTN

Vail Resorts

$222.31

3.37 (1.54%)

08:38
01/16/18
01/16
08:38
01/16/18
08:38
Recommendations
Vail Resorts analyst commentary  »

Vail Resorts price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$42.81

-0.01 (-0.02%)

, INTC

Intel

$43.24

-0.17 (-0.39%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Recommendations
Micron, Intel analyst commentary  »

Micron pullback a buying…

MU

Micron

$42.81

-0.01 (-0.02%)

INTC

Intel

$43.24

-0.17 (-0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 24

    Jan

  • 25

    Jan

  • 26

    Mar

ATTU

Attunity

$6.71

-0.061 (-0.90%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Attunity wins $1.2M in additional business with Fortune 100 company »

Attunity announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OTIV

On Track Innovations

$1.37

-0.01 (-0.72%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
On Track Innovations announces additional order of 10,000 cashless readers »

On Track Innovations…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYF

Synchrony

$39.37

-0.39 (-0.98%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Hot Stocks
Synchrony reports December charge-off rate 4.94% vs. 5.03% last month »

Reports December 30-plus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

F

Ford

$13.23

0.07 (0.53%)

08:37
01/16/18
01/16
08:37
01/16/18
08:37
Periodicals
Ford sees savings in 'every part' of business, FT reports »

Ford will have to make…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 24

    Jan

MDXG

MiMedx

$13.86

-0.08 (-0.57%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
MiMedx: First patients enrolled in Phase 3 clinical trial of AmnioFix Injectable »

MiMedx Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:36
01/16/18
01/16
08:36
01/16/18
08:36
Hot Stocks
Ultra Clean sees Q1 revenue up from Q4 »

The company said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Hot Stocks
Breaking Hot Stocks news story on Long Blockchain Corp. »

Long Blockchain…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRAY

Cray

08:35
01/16/18
01/16
08:35
01/16/18
08:35
Earnings
Cray sees FY17 revenue about $390M, consensus $399.96M »

Cray announced selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LNG

Cheniere Energy

$54.73

0.29 (0.53%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Cheniere Energy, Trafigura sign 15-year LNG sale and purchase agreement »

Cheniere Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

UCTT

Ultra Clean

$23.22

0.47 (2.07%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Earnings
Ultra Clean reaffirms Q4 revenue view $240.0M-$250M, consensus $244.32M »

Sees Q4 operating margins…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PX

Praxair

$164.15

0.34 (0.21%)

08:34
01/16/18
01/16
08:34
01/16/18
08:34
Hot Stocks
Praxair expands hydrogen supply to Motiva Port Arthur, Texas refinery »

Praxair, Inc. has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

, INCY

Incyte

$94.07

1.01 (1.09%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Downgrade
Concert Pharmaceuticals, Incyte rating change  »

Concert Pharmaceuticals…

CNCE

Concert Pharmaceuticals

$20.15

-7.53 (-27.20%)

INCY

Incyte

$94.07

1.01 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

, LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Recommendations
MGM Resorts, Las Vegas Sands, Wynn Resorts, Melco Resorts & Entertainment analyst commentary  »

Morgan Stanley raises…

MGM

MGM Resorts

$35.03

-0.08 (-0.23%)

LVS

Las Vegas Sands

$71.02

0.39 (0.55%)

WYNN

Wynn Resorts

$165.54

3.04 (1.87%)

MLCO

Melco Resorts & Entertainment

$27.01

-0.21 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRWD

Ironwood

$15.12

0.02 (0.13%)

, AGN

Allergan

$176.05

-1.07 (-0.60%)

08:33
01/16/18
01/16
08:33
01/16/18
08:33
Hot Stocks
Ironwood, Allergan announce settlement with Sun Pharma over LINZESS »

Ironwood Pharmaceuticals…

IRWD

Ironwood

$15.12

0.02 (0.13%)

AGN

Allergan

$176.05

-1.07 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 16

    Feb

  • 25

    Mar

YUMC

Yum China

$45.86

2.06 (4.70%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
Yum China sees one-time tax expense of approximately $160M in Q4 »

Yum China Holdings is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

IO

ION Geophysical

$21.35

-2.7 (-11.23%)

08:32
01/16/18
01/16
08:32
01/16/18
08:32
Hot Stocks
ION Geophysical announces Supreme Court granted certiorari »

ION Geophysical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OSIS

OSI Systems

$67.68

0.19 (0.28%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Hot Stocks
OSI Systems signs 2-year contract to continue turnkey screening services »

OSI Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

, TSRO

Tesaro

$69.59

-2.07 (-2.89%)

08:31
01/16/18
01/16
08:31
01/16/18
08:31
Recommendations
Heron Therapeutics, Tesaro analyst commentary  »

Tesaro update could drive…

HRTX

Heron Therapeutics

$21.40

-0.25 (-1.15%)

TSRO

Tesaro

$69.59

-2.07 (-2.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:31
01/16/18
01/16
08:31
01/16/18
08:31
General news
Empire State Mfg Survey General Business Conditions Index data reported »

January Empire State Mfg…

LMOS

Lumos Networks

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Hot Stocks
Lumos signs multi-year contract with Roanoke Blacksburg Regional Airport »

Lumos Networks signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$77.60

1.94 (2.56%)

, BOBE

Bob Evans

08:30
01/16/18
01/16
08:30
01/16/18
08:30
Options
One new option listing and three option delistings on January 16th »

New option listings for…

WP

Worldpay

$77.60

1.94 (2.56%)

BOBE

Bob Evans

SYT

Syngenta

VNTV

Vantiv

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.